Synthesis of amide derivatives of 3-aryl-3H-benzopyrans as osteogenic agent concomitant with anticancer activity

Bioorg Chem. 2023 Apr:133:106380. doi: 10.1016/j.bioorg.2023.106380. Epub 2023 Jan 21.

Abstract

The present study reports a series of 3-aryl-3H-benzopyran-based amide derivatives as osteogenic agents concomitant with anticancer activity. Six target compounds viz 22e, 22f, 23i, and 24b-d showed good osteogenic activity at 1 pM and 100 pM concentrations. One of the potential molecules, 24b, effectively induced ALP activity and mRNA expression of osteogenic marker genes at 1 pM and bone mineralization at 100 pM concentrations. These molecules also presented significant growth inhibition of osteosarcoma (MG63) and estrogen-dependent and -independent (MCF-7 and MDA-MB-231) breast cancer cells. The most active compound, 24b, inhibited the growth of all the cancer cells within the IC50 10.45-12.66 µM. The mechanistic studies about 24b showed that 24b induced apoptosis via activation of the Caspase-3 enzyme and inhibited cancer cell migration. In silico molecular docking performed for 24b revealed its interaction with estrogen receptor-β (ER-β) preferentially.

Keywords: 3-aryl-3H-benzopyran; Anti-estrogen; Benzopyran; Estrogen; Isoflavonoids; Osteogenic; Tamoxifen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Benzopyrans* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Estrogen Receptor beta / metabolism
  • Molecular Docking Simulation

Substances

  • Benzopyrans
  • Amides
  • Antineoplastic Agents
  • Estrogen Receptor beta